Turkmenistan

Turkmenistan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.65 (2.23 - 3.02) 2019 Modelled IHME
2.67 (2.31 - 3.05) 2018 Modelled IHME
2.72 (2.33 - 3.12) 2017 Modelled IHME
2.81 (2.40 - 3.23) 2016 Modelled IHME
2.92 (2.43 - 3.39) 2015 Modelled IHME
3.03 (2.52 - 3.51) 2014 Modelled IHME
3.14 (2.62 - 3.63) 2013 Modelled IHME
3.26 (2.74 - 3.75) 2012 Modelled IHME
3.37 (2.83 - 3.90) 2011 Modelled IHME
3.47 (2.90 - 4.05) 2010 Modelled IHME
3.56 (2.97 - 4.15) 2009 Modelled IHME
3.65 (3.03 - 4.27) 2008 Modelled IHME
3.74 (3.08 - 4.38) 2007 Modelled IHME
3.82 (3.12 - 4.49) 2006 Modelled IHME
3.89 (3.14 - 4.59) 2005 Modelled IHME
3.96 (3.19 - 4.65) 2004 Modelled IHME
4.01 (3.21 - 4.69) 2003 Modelled IHME
4.06 (3.26 - 4.75) 2002 Modelled IHME
4.11 (3.26 - 4.81) 2001 Modelled IHME
4.18 (3.30 - 4.90) 2000 Modelled IHME
4.28 (3.40 - 4.99) 1999 Modelled IHME
4.42 (3.54 - 5.13) 1998 Modelled IHME
4.56 (3.68 - 5.31) 1997 Modelled IHME
4.66 (3.77 - 5.45) 1996 Modelled IHME
4.71 (3.80 - 5.54) 1995 Modelled IHME
4.7 (3.80 - 5.49) 1994 Modelled IHME
4.67 (3.76 - 5.46) 1993 Modelled IHME
4.62 (3.68 - 5.42) 1992 Modelled IHME
4.54 (3.59 - 5.35) 1991 Modelled IHME
4.42 (3.43 - 5.29) 1990 Modelled IHME
1.85 (0.19 - 12.57) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.38 (0.28 - 0.46) 2019 Modelled IHME
0.41 (0.27 - 0.51) 2018 Modelled IHME
0.42 (0.27 - 0.55) 2017 Modelled IHME
0.42 (0.27 - 0.56) 2016 Modelled IHME
0.43 (0.28 - 0.58) 2015 Modelled IHME
0.44 (0.29 - 0.61) 2014 Modelled IHME
0.47 (0.32 - 0.64) 2013 Modelled IHME
0.51 (0.35 - 0.67) 2012 Modelled IHME
0.54 (0.37 - 0.71) 2011 Modelled IHME
0.56 (0.38 - 0.73) 2010 Modelled IHME
0.55 (0.38 - 0.72) 2009 Modelled IHME
0.55 (0.37 - 0.71) 2008 Modelled IHME
0.54 (0.36 - 0.71) 2007 Modelled IHME
0.54 (0.35 - 0.71) 2006 Modelled IHME
0.54 (0.34 - 0.71) 2005 Modelled IHME
0.8 (0.51 - 1.06) 2004 Modelled IHME
1.44 (0.91 - 1.90) 2003 Modelled IHME
2.24 (1.41 - 2.96) 2002 Modelled IHME
2.96 (1.87 - 3.90) 2001 Modelled IHME
3.39 (2.17 - 4.45) 2000 Modelled IHME
3.59 (2.34 - 4.65) 1999 Modelled IHME
3.77 (2.48 - 4.84) 1998 Modelled IHME
3.91 (2.60 - 4.98) 1997 Modelled IHME
4 (2.68 - 5.10) 1996 Modelled IHME
4.03 (2.69 - 5.15) 1995 Modelled IHME
4.02 (2.69 - 5.10) 1994 Modelled IHME
3.98 (2.66 - 5.05) 1993 Modelled IHME
3.91 (2.58 - 4.99) 1992 Modelled IHME
3.8 (2.46 - 4.87) 1991 Modelled IHME
3.64 (2.31 - 4.73) 1990 Modelled IHME
0.23 (0.02 - 1.76) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
28 (21 - 36) 2019 Modelled IHME
28 (21 - 36) 2018 Modelled IHME
28 (21 - 36) 2017 Modelled IHME
28 (21 - 36) 2016 Modelled IHME
28 (21 - 37) 2015 Modelled IHME
28 (22 - 37) 2014 Modelled IHME
29 (22 - 37) 2013 Modelled IHME
30 (23 - 38) 2012 Modelled IHME
30 (23 - 39) 2011 Modelled IHME
30 (24 - 39) 2010 Modelled IHME
31 (24 - 39) 2009 Modelled IHME
30 (23 - 39) 2008 Modelled IHME
30 (23 - 39) 2007 Modelled IHME
30 (23 - 38) 2006 Modelled IHME
30 (23 - 38) 2005 Modelled IHME
29 (22 - 38) 2004 Modelled IHME
29 (22 - 37) 2003 Modelled IHME
29 (22 - 37) 2002 Modelled IHME
28 (21 - 36) 2001 Modelled IHME
27 (21 - 36) 2000 Modelled IHME
26 (19 - 34) 1999 Modelled IHME
25 (19 - 33) 1998 Modelled IHME
24 (18 - 32) 1997 Modelled IHME
24 (18 - 32) 1996 Modelled IHME
23 (17 - 31) 1995 Modelled IHME
23 (17 - 31) 1994 Modelled IHME
23 (17 - 31) 1993 Modelled IHME
22 (16 - 30) 1992 Modelled IHME
22 (16 - 29) 1991 Modelled IHME
22 (16 - 29) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
98 2002 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
97 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
96 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
96 2004 Survey/reported WHO/UNICEF
97 2003 Survey/reported WHO/UNICEF
96 2002 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2014 Survey/reported Boltaev AA et al, 2013

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2013 Survey/reported Boltaev AA et al, 2013
HBV elimination goal
HBV National Action Plan
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
No
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.91 (3.19 - 4.77) 2019 Modelled IHME
3.91 (3.18 - 4.77) 2018 Modelled IHME
3.9 (3.15 - 4.76) 2017 Modelled IHME
3.89 (3.16 - 4.74) 2016 Modelled IHME
3.88 (3.15 - 4.77) 2015 Modelled IHME
3.89 (3.16 - 4.78) 2014 Modelled IHME
3.92 (3.20 - 4.77) 2013 Modelled IHME
3.95 (3.23 - 4.82) 2012 Modelled IHME
3.98 (3.24 - 4.87) 2011 Modelled IHME
3.99 (3.23 - 4.89) 2010 Modelled IHME
3.98 (3.24 - 4.89) 2009 Modelled IHME
3.96 (3.23 - 4.87) 2008 Modelled IHME
3.94 (3.22 - 4.85) 2007 Modelled IHME
3.92 (3.21 - 4.84) 2006 Modelled IHME
3.92 (3.20 - 4.85) 2005 Modelled IHME
3.92 (3.20 - 4.82) 2004 Modelled IHME
3.92 (3.19 - 4.81) 2003 Modelled IHME
3.93 (3.19 - 4.79) 2002 Modelled IHME
3.93 (3.18 - 4.81) 2001 Modelled IHME
3.94 (3.18 - 4.83) 2000 Modelled IHME
3.94 (3.20 - 4.84) 1999 Modelled IHME
3.95 (3.21 - 4.84) 1998 Modelled IHME
3.97 (3.21 - 4.86) 1997 Modelled IHME
3.97 (3.23 - 4.89) 1996 Modelled IHME
3.98 (3.22 - 4.92) 1995 Modelled IHME
3.98 (3.22 - 4.88) 1994 Modelled IHME
3.98 (3.25 - 4.85) 1993 Modelled IHME
3.97 (3.24 - 4.83) 1992 Modelled IHME
3.97 (3.23 - 4.88) 1991 Modelled IHME
3.96 (3.21 - 4.91) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
5.6 (1.10 - 6.70) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
30 (21 - 39) 2019 Modelled IHME
30 (21 - 39) 2018 Modelled IHME
30 (21 - 39) 2017 Modelled IHME
30 (21 - 38) 2016 Modelled IHME
30 (22 - 39) 2015 Modelled IHME
30 (22 - 38) 2014 Modelled IHME
30 (22 - 38) 2013 Modelled IHME
30 (22 - 38) 2012 Modelled IHME
30 (22 - 38) 2011 Modelled IHME
30 (22 - 38) 2010 Modelled IHME
30 (22 - 38) 2009 Modelled IHME
30 (22 - 39) 2008 Modelled IHME
31 (23 - 39) 2007 Modelled IHME
31 (23 - 40) 2006 Modelled IHME
32 (23 - 40) 2005 Modelled IHME
32 (24 - 40) 2004 Modelled IHME
32 (24 - 41) 2003 Modelled IHME
33 (24 - 41) 2002 Modelled IHME
33 (24 - 41) 2001 Modelled IHME
33 (24 - 41) 2000 Modelled IHME
33 (25 - 41) 1999 Modelled IHME
33 (25 - 42) 1998 Modelled IHME
34 (25 - 42) 1997 Modelled IHME
34 (25 - 42) 1996 Modelled IHME
34 (25 - 42) 1995 Modelled IHME
34 (26 - 42) 1994 Modelled IHME
34 (26 - 42) 1993 Modelled IHME
34 (26 - 42) 1992 Modelled IHME
34 (26 - 42) 1991 Modelled IHME
34 (26 - 42) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2014 Survey/reported Boltaev AA et al, 2013

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2013 Survey/reported Boltaev AA et al, 2013
HBV elimination goal
HBV National Action Plan
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
No
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.65 (%)
2019
(2.23 - 3.02(%))
IHME
HCV (RNA/cAg+)
3.91 (%)
2019
(3.19 - 4.77(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
502
2019
(356 - 695)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
580
2019
(414 - 798)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.38 (%)
2019, latest modelled
(0.28 - 0.46(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2014
(0 - 0)
Boltaev AA et al, 2013
Eligible for HBV generic medicines
Eligible for HCV generic medicines